The diabetes-linked transcription factor Pax4 is expressed in human pancreatic islets and is activated by mitogens and GLP-1

Thierry Brun¹, Kai Hui Hu He¹, Roberto Lupi³, Bernhard Boehm⁴, Anne Wojtusciszyn², Nadine Sauter⁵, Marc Donath⁶, Piero Marchetti³, Kathrin Maedler⁵ and Benoit R. Gauthier¹,*

¹Department of Cell Physiology and Metabolism and ²Department of Surgery, University Medical Center, 1211 Geneva 4, Switzerland, ³Department of Endocrinology and Metabolism, Metabolic Unit, University of Pisa, Pisa, Italy, ⁴Division of Endocrinology and Diabetes, Ulm University, Ulm, Germany, ⁵Larry L Hillblom Islet Research Center, University of California, Los Angeles, California, USA and ⁶Division of Endocrinology and Diabetes, University Hospital Zurich, Zurich, Switzerland

Received September 5, 2007; Revised and Accepted November 6, 2007

INTRODUCTION

The ultimate goal in the management of diabetes is to achieve optimal glucose control while avoiding hypoglycaemia. Human islet transplantation has provided proof of principle that it is feasible to partially normalize blood glucose in Type 1 diabetic patients (1). However, this approach is severely hampered by the shortage of donor pancreata and thus alternative sources of cells as well as protocols are required to generate new surrogate β-cells. The encouraging, yet controversial results obtained to date with either embryonic or adult stem cells, necessitate re-evaluation of approaches to be taken in order to produce safe and fully differentiated insulin-producing cells in vitro (2). More recently, in vivo cell regeneration has gained attention with the finding that residual β-cells are detected in long standing Type 1 diabetic patients (3,4). Consistent with the latter, we and others have proposed that β-cells can replicate and most likely constitute the main venue of cell regeneration under physiological conditions (5–8). Harnessing signals and factors involved in controlling β-cell replication to restore glucose homeostasis in Type 1 diabetic patients would circumvent the need for...
insulin therapy or invasive surgery. Individuals with Type 2 diabetes would also benefit from agents that protect or expand β-cell mass, as several studies have clearly demonstrated a significant decrease in insulin-producing cells in these patients (9,10).

Of particular interest is the β-cell transcription factor Pax4 for which polymorphisms and mutations have been associated with Types 1 and 2 diabetes, respectively (11–17). Consistent with the oncogenic function of other pax genes in human cancer (18), we have demonstrated that Pax4 is a key regulator of β-cell plasticity (5). Mitogens such as activin A or betacellulin induced Pax4 expression with a concomitant increase in rat β-cell replication. Overexpression of murine Pax4 in rat as well as in human islets induced β-cell proliferation and conferred protection against cytokine-induced apoptosis. These beneficial effects were conveyed by increased Bcl-xL (an anti-apoptotic gene), c-myc (a proto-oncogene) and Id2 (a c-myc target gene) mRNA levels in rat islets (5). Similarly, the purified recombinant Pax4 protein was recently found to permeate into human cell lines as well as pancreatic islets and subsequently activate Bcl-xL and c-myc (19). Interestingly, low concentrations of IL-1β induced both endogenous Pax4 transcription and β-cell proliferation whereas high levels of the cytokine inhibited expression of the transcription factor and induced apoptosis in human islets (20). The latter findings indicate an initial beneficial effect of cytokines on islet mass whereas higher levels become detrimental, a phenomenon potentially mimicking the in vivo conditions of both Types 1 and 2 diabetic patients (21).

Although our previous studies clearly indicate that Pax4 is an important molecular mediator relaying physiological cues to islet mass adaptation, no data on the effects of endogenous Pax4 on human islet cell proliferation are available. Therefore, in the present study, we investigated the expression of Pax4 in islets of non-diabetic and diabetic patients, its regulation by mitogens, glucose and the incretin GLP-1 as well as evaluating its effect on cell replication.

RESULTS

Pax4 is expressed in human pancreatic islets and is increased in Type 2 diabetic patients with BMI between 22 and 26

In order to determine whether Pax4 expression was modulated in pathophysiological conditions such as hyperglycaemia and/or obesity, Pax4 transcript levels were evaluated in islets freshly isolated from a small cohort of Type 2 diabetic donors and related to body mass index (BMI). Pax4 transcript was detected in human islets and increased 10-fold in diabetic donors with a BMI between 22 and 26 when compared with control non-diabetic donors (Fig. 1; 5.7 ± 2.8 versus 0.5 ± 0.1, P < 0.05). In contrast to BMI, no correlation between Pax4 mRNA levels and age or sex could be established. Although few donors were analysed, no changes in Pax4 mRNA levels were detected in either group with BMI greater than 26. Noteworthy, control islets exhibited astonishingly small variations in Pax4 mRNA levels independent of BMI. These results suggest that hyperglycaemia is most likely sufficient to induce Pax4 expression in Type 2 diabetic donors whereas long-term adiposity appears to favour suppression of the gene.

To determine whether development of Type 2 diabetes in donors with increased levels of Pax4 could be potentially correlated to polymorphisms and/or mutations associated with the disease (12–15,17), DNA isolated from seven donors (four diabetics and three non-diabetics) were sequenced in regions of interest in the pax4 gene. Individual diabetes-linked polymorphisms or mutations could not be identified within the paired domain of the pax4 gene (data not shown). Interestingly, three of the four Type 2 diabetic donors as well as two of the three non-diabetic donors carried a previously described single nucleotide polymorphism (SNP rs698406; G to C) at position 1298 (relative to the transcriptional initiation site). This SNP is located within intron 3 and has not yet been assigned any functional phenotype.

Glucose-induced insulin release stimulates Pax4 gene transcription in human islets

To validate the hypothesis that glucose is responsible for the in vivo up-regulation of Pax4 expression, primary culture of human control islets were exposed to increasing concentrations of glucose for 24 and 48 h. A 3-fold increase in Pax4 mRNA levels was observed in islets treated with 25 mM glucose, whereas transcript levels returned to basal values at 33 mM glucose (Fig. 2A). No significant differences in the induction of Pax4 expression were observed between 24 and 48 h. Correspondingly, Ipf1 mRNA levels also exhibited a bell-shaped expression pattern reaching maximal induction of approximately 2-fold at 25 mM glucose before decreasing to basal levels at 33 mM glucose. We have previously demonstrated that low concentrations of IL-1β via the FAS-FLIP signalling pathway induced Pax4 expression, whereas high concentrations inhibited mRNA levels of the transcription factor (20). Corroborating these studies, we found that
glucose dose dependently induced IL-1β and FAS transcript levels reaching maximal induction of 5- and 3-fold, respectively, at 33 mM glucose whereas the expression pattern of the caspase-8 inhibitor FLIP mimicked that of Pax4 (Fig. 2C). These results suggest that islets exposed to elevated glucose concentrations such as in Type 2 diabetic patients will produce increasing amounts of IL1-β and FAS ultimately inhibiting pax4 gene transcription and induce cell death (20).

As the predominant function of glucose metabolism in β-cells is to promote insulin secretion which may then have an autocrine effect on islet cells, we investigated whether insulin could stimulate Pax4 expression. Addition of exogenous insulin in the presence of 5.6 mM glucose whereas the expression pattern of the caspase-8 inhibitor FLIP mimicked that of Pax4 (Fig. 2C). These results suggest that islets exposed to elevated glucose concentrations such as in Type 2 diabetic patients will produce increasing amounts of IL1-β and FAS ultimately inhibiting pax4 gene transcription and induce cell death (20).

Pax4 expression in human islets is induced by activin A, betacellulin and GLP-1

In order to determine whether other growth factors stimulated pax4 gene expression, human islets were cultured in the presence of either activin A (a member of the TGF-β family) or betacellulin (a member of the EGF family). Pax4 mRNA levels were increased by approximately 5-fold in islets treated with either 0.5 nM activin A or betacellulin for 24 or 48 h (Fig. 3A). Interestingly, the combination of activin A and betacellulin in the presence of either 5.6 or 15 mM glucose did not further increase Pax4 expression when

---

**Figure 2.** Glucose stimulates Pax4 gene expression in isolated human islets. (A) Pax4, (B) Ipf1, (C) IL-1β, Fas and FLIP mRNA levels in islets treated with increasing doses of glucose as indicated in the figure legends. Quantitative RT-PCR using RNA purified from cultured human islets was performed on Pax4 and the mentioned genes. Data are presented as fold change of mRNA levels when compared with 5.6 mM Glc normalized to the cyclophilin transcript. Values represent the mean ± SEM of 3–5 independent experiments performed in duplicates. (D) and (E) Islets were incubated with 5.6 mM Glc in the absence or presence of insulin (50 nM) or with 15 mM Glc in the absence or presence of the non-selective K$_{ATP}$ channel opener diazoxide (250 μM). (D) Pax4 and (E) Ipf1 transcripts abundance levels were estimated by quantitative RT-PCR. Statistical significance was tested by Student's t-test. *P < 0.05; **P < 0.01.
compared with individual mitogens (data not shown). As in rat islets (5), TGF-β1 had no consequence on Pax4 expression. Ipf1 mRNA levels were not significantly increased by activin A, betacellulin or TGF-β1 treatments (Fig. 3B). We next determine the impact of GLP-1, a new therapeutic agent for the treatment of diabetes which has been shown to increase β-cell mass in mouse and rat pancreas as well as promoting cell proliferation in INS-1 cells (23–27). GLP-1 (10 nM) in combination with 5.6 mM glucose had no stimulatory effect while in the presence of 15 mM glucose the incretin elicited a 6-fold increase in Pax4 mRNA levels at either 24 or 48 h (Fig. 3C). This increase was significantly greater than that of 15 mM glucose alone at 24 h indicating that GLP-1 potentiated the effect of the sugar on Pax4 stimulation. Similar results were obtained with the long acting analogue of GLP-1, exendin-4 (data not shown).

Investigation as to which particular secondary signal might evoke an increase in Pax4 expression in response to glucose alone or in combination with the incretin was then conducted. Inhibition of the PI3K pathway with LY294002 repressed both glucose and glucose/GLP-1-mediated increase in Pax4 expression (Fig. 3E). Likewise, Pax4 induction was completely blunted by the MEK1/2 specific inhibitor PD98059 which blocks the ERK1/2 axis of the insulin signalling pathway (Fig. 3E). To determine the contribution of the cAMP-PKA pathway in the stimulation of Pax4 expression, islets cultured in the presence of 15 mM glucose with or without of GLP-1 were treated with the PKA-specific inhibitor H89. Induction of Pax4 expression was abrogated in the presence of H89 (Fig. 3E). Taken together, these results indicate that glucose most likely via insulin enhance Pax4 expression through activation of both the ERK1/2 and PI3K branches of the insulin signalling cascade as well as the cAMP-PKA pathway. As cross talk between these three pathways has previously been established (28), incapacitating any one cascade results in complete inhibition of Pax4. Complete inhibition of

Figure 3. Activin A, betacellulin and the incretin GLP-1, in combination with glucose, increase Pax4 mRNA levels in human islets. (A) Pax4 and (B) Ipf1 mRNA levels in islets treated with activin A, betacellulin or TGF-β1 as indicated in the figure legend. Quantitative RT–PCR analysis was performed as described in Figure 2. (C) Pax4 and (D) Ipf1 mRNA levels in islets incubated with glucose in the absence or presence of GLP-1 (10 nM), as indicated on the graph. (E) Pax4 and (F) Ipf1 mRNA levels in islets incubated with glucose, GLP-1, the PI3-kinase inhibitor LY294002, the MEK1/2 specific inhibitor PD98059 and the PKA-specific inhibitor H89, as indicated on the graph. The results are normalized to cyclophilin and are expressed as fold change of mRNA when compared with control. Data are expressed as the mean ± SEM of four independent experiments. *P < 0.05; **P < 0.01.
the stimulatory effect of GLP-1 in combination with 15 mM
glucose on Pax4 expression confirms the strict dependency
of the incretin action on the presence of the sugar.

Surprisingly, glucose-mediated stimulation of Ipf1 expression
was not further increased by the addition of GLP-1 (Fig. 3F). Fur-
thermore, PD98059 and H89 but not LY294002 inhibited induc-
tion of Ipf1 expression by glucose indicating that, in contrast to
Pax4, stimulation of Ipf1 is not dependent on the PI3K pathway.

Mitogens and GLP-1-mediated activation of endogenous
Pax4 does not increase human β-cell proliferation

We have previously demonstrated that stimulation of pax4 gene
expression by activin A and betacellulin coincided with rat islet
cell proliferation (5). In parallel, GLP-1 was previously shown
to stimulate rodent and murine β-cell replication (29,30). Thus,
to determine whether mitogens- and GLP-1-elicted increases
in Pax4 expression levels correlated with induction of human
islet cell replication, Brdu-incorporation was evaluated in
islets treated with various growth factors. Consistent with a pre-
vious study, we found that the total number of islet cells under-
going proliferation under non-stimulatory conditions was
∼0.5% (Fig. 4A) (31). Astonishingly, addition of activin A, betacellulin or GLP-1 failed to induce replication (Fig. 4A).

Longer incubation time in the presence of BrdU and growth
factors (alone or in combination) as well as culturing cells on
various substrata (up to 6 days) did not improve yield of
labelled cells (data not shown). In contrast, rat islets exposed
to GLP-1 or activin A displayed a 2.5-fold increase in BrdU-
labelling while betacellulin elicited a 3-fold increase when
compared with control 5.6 mM treated islets (Fig. 4B).

To address the possibility that human islet β-cells are refrac-
tory to these physiological stimuli in vitro, we investigated
whether nuclear translocation of the proliferation marker Id2
(32,33) occurred in activin A treated islets. As expected, under
control conditions Id2 was predominantly localized to the cyto-
plasm of both human and rat islet cells, whereas addition of
activin A prompted nuclear translocation of the protein
(Fig. 4C and D). Interestingly, translocation was only observed
in β-cells despite presence of Id2 in all cell types. These
results suggest that human β-cells are responsive to mitogens
such activin A resulting in Pax4 stimulation and Id2 nuclear
translocation but fail to subsequently enter into the S-phase.

Human islet proliferation is not significantly induced by
adenoviral-mediated overexpression of human Pax4

In order to investigate whether supra-physiological levels of
human Pax4 could force entry of cells into the replication
phase, human islets were infected with a doxycycline induc-
able adenoviral construct bearing the human Pax4 cDNA
tagged with a myc epitope. The latter was essential to
reveal Pax4 by immunocytochemistry as no reliable antibodies
for the transcription factor are commercially available. A
14-fold increase in Pax4 transcript levels was estimated sub-
sequent to doxycycline treatment corresponding to a 2-fold
increment when compared with islets incubated with activin
A or betacellulin (compare Fig. 5A to 3A). Consistent with
our previous studies in rat islets (5), overexpression of Pax4
did not alter Ipf1 mRNA levels. Interestingly, a small but

significant 1.6-fold increase in transcript levels of the
Pax4-target gene, Bcl-xL was found in doxycycline treated
islets whereas Id2 mRNA levels maintained basal values
when compared with untreated islets (Fig. 5B). The latter
results would tend to suggest that human Pax4, in contrast to
the mouse variant (5), is less efficient in activating downstream
target genes and thus to stimulate proliferation. Consistent with
this hypothesis, immunocytochemistry revealed that although
Pax4 was expressed in ∼60% of cell nuclei after doxycycline
treatment (Fig. 5C), no significant increase in BrdU labelling
could be discerned when compared with control untreated
islets (Fig. 5D and E). In contrast, human islets transduced
with the mouse variant of Pax4 employing the same viral trans-
duction system, displayed a 10-fold increase in islet cell replica-
tion (Fig. 5F). As an activator and/or repressor domain was
previously identified at the carboxy-terminal end of Pax4
(34), we investigated whether activin A may be required to acti-
vate the transcription factor and increase proliferation in trans-
duced islets. No further increase in BrdU labelling was
discerned in these islets when compared with non-induced
Ad-hPax4-myc-infected islets (Fig. 5E). Similar attempts to
stimulate proliferation in the presence of betacellulin and
GLP-1 also failed (data not shown).

We next evaluated the capacity of both the human and mouse
Pax4 to promote cell replication in rat islets. Subsequent to
infection and doxycycline treatment, 70% of islet cells
expressed either recombinant protein (Fig. 6A). However, simi-
larly to human islets, only mouse Pax4 was capable of stimulat-
ing proliferation suggesting potential post translational modi-
fications of the human protein that modulates its activity.

Pax4 gene expression in human and rat islets
is regulated by epigenetic modifications

Aberrant DNA demethylation in the pax4 gene promoter was
recently shown to induce expression of the transcription factor
in lymphocytes and promote haematologic malignancies (35).
Furthermore, a member of the id gene family, Id4 was also
found to be regulated by epigenetic modifications (36).

These findings suggest that Pax4 expression as well as down-
stream target genes may be epigenetically regulated in human
islets thereby blocking activation of the replication program.

Consistent with this premise, human islets treated with
increasing concentrations of the DNA methyltransferase
inhibitor, 5-Aza-2′-deoxycytidine (5′-AZA) for 72 h exhibited
a gradual increase in Pax4 mRNA levels reaching maximal
induction of 3-fold with 20 μM of the drug (Fig. 7A). In con-
trast, Ipf1 mRNA levels were unaltered. Nonetheless, neither
Bcl-xL nor Id2 gene expression was increased in the presence
of 5′-AZA (Fig. 7B). In contrast, a 10-fold stimulation in Pax4
transcript levels as well as a concomitant increase of 2.5- and
3-fold in Id2 and Bcl-xL gene expression was observed in rat
islets incubated with 10 μM 5′-AZA (Fig. 7C and D). These
results highlight a novel regulatory mechanism of pax4 gene
expression through epigenetic modification in rat and human
islets. However, alleviation of this regulatory checkpoint was
still not sufficient to activate downstream target genes. The
latter conclusion combined with the adenoviral transduction
studies showing a modest increase in only Bcl-xL transcript
in the presence of supra physiological levels of human Pax4,
prompt us to investigate whether the human Pax4 protein when compared with the rat or mouse variant might be less efficient in trans-activating target genes. Electrophoretic mobility shift assays (EMSAs) using equal amounts of recombinant mouse and human Pax4 (Fig. 7F) revealed a much stronger binding of the mouse variant to the glucagon gene promoter element G3 (Fig. 7E) when compared with the human protein. The latter therefore substantiates the concept that the human protein is a poor trans-activator and requires much higher levels than its murine counterpart to stimulate transcription and most likely proliferation.

DISCUSSION
The beneficial effect of Pax4 on β-cell replication and survival has been well established in rodent islets. A similar positive outcome was also demonstrated in human islets in which murine Pax4 was overexpressed using adenovirus (5). However, regulation of endogenous pax4 gene as well as its functional role in human islet plasticity under physiological or pathophysiological conditions remains obscure. Herein we show that islets derived from Type 2 diabetic donors with BMI between 22 and 26 have elevated levels of Pax4 transcript when compared with non-diabetic controls whereas expression levels are indistinguishable between the two groups with BMI greater than 26. Previous work reported a slight increase in Pax4 expression in Type 2 diabetes islets relative to controls (37). The relatively stable expression level of Pax4 in non-diabetic patients across BMI values suggests that hyperglycaemia acts as an important inducer of Pax4 expression and potentially cell replication in diabetic islets. Consistent with this premise, Pax4 expression was
stimulated in human islets cultured in either 11 or 25 mM glucose while transcript levels returned to basal levels with higher concentrations. A similar bell-shaped Pax4 expression pattern was reported in human islets cultured with increasing concentrations of IL-1β. Indeed, low concentrations of the cytokine correlated with enhanced Pax4 expression and improved islet function whereas high levels inhibited Pax4 and induced apoptosis (20). In the current study, we show that IL-1β and its downstream target FAS were dose-dependently increased by glucose. It is therefore tempting to speculate that initial increases in Pax4 expression detected in human diabetic islets could be partly conveyed by glucose-induced IL-1β generation and release, whereas chronic exposure to the cytokine becomes inhibitory and detrimental to cells. The latter would also corroborate with the observation that Type 2 diabetic islets expressed the cytokine as a result of hyperglycaemia (38). We also demonstrate that insulin released in response to high glucose plays a pivotal...
role in stimulating Pax4 expression. The latter correlates with recent findings showing that exogenous insulin protects human islets from apoptosis induced by serum withdrawal (22). Interestingly, islets of Type 2 diabetic donors with BMI values greater than 26 exhibited Pax4 mRNA levels identical to those of non-diabetic islets suggesting that adiposity may repress hyperglycaemia-induced Pax4 expression. Of note, palmitate known to be elevated in plasma of obese individuals, has been reported to attenuate human islet apoptosis induced by serum withdrawal (22). Interestingly, islets of Type 2 diabetic donors with BMI values greater than 26 exhibited Pax4 mRNA levels identical to those of non-diabetic islets suggesting that adiposity may repress hyperglycaemia-induced Pax4 expression. Of note, palmitate known to be elevated in plasma of obese individuals, has been reported to attenuate human islet apoptosis induced by serum withdrawal (22).

Figure 6. Adenoviral-mediated overexpression of human Pax4 does not stimulate replication in rat islets. Rat islets were infected with either Ad-hPax4-myc or Ad-mousePax4-myc and Ad-X Tet-On as described in Materials and Methods. Doxycycline-dependent activation of Pax4 was then assessed 48 h later by (A) immunohistochemistry; myc epitope (green), insulin (red) and DAPI (blue). Bars, 50 μm. (B) Islet cell proliferation was measured by BrDU incorporation in rat islets infected with Ad-hPax4-myc or with Ad-mousePax4-myc and cultured with (0.5 μg/ml) or without doxycycline in the presence of BrDU (10 μM) for 4 days. Dispersed islet cells immunostained for BrDU were counted and results are depicted as a percentage of BrDU positive cells over the total amount of cells. Data show the mean ± SE of four independent experiments, each representing more than 800 cells per condition. **P < 0.01.

in vivo subsequent to prolonged culture time (42,43). However, we discovered that Pax4 expression was regulated by epigenetic modification which may impose restriction on the level of transcriptional activation by various stimuli in human islets. It will be of interest to determine whether combined treatment of islets with mitogens and 5′-AZA induces Pax4 expression to levels detected in rat islets. Addition of GLP-1 to 15 mM glucose further increased Pax4 mRNA levels indicating that the incretin potentiates the effect of glucose. This induction was found to be dependent on cAMP/ PKA, ERK1/2 and PI3K activities suggesting that extensive cross talk between the G-protein coupled receptor and tyrosine coupled receptor transduction pathways is taking place before converging onto Pax4. Consistent with the premise that the effect of GLP-1 is glucose dependent, all three inhibitors completely abrogated the glucose-mediated stimulation of Pax4. Friedrichsen et al. (30) have recently demonstrated that GLP-1 induced cyclin D1 gene transcription in rat islets with the subsequent induction of β-cell replication. Interestingly, the latter effects were completely blocked by the inhibitors LY294002, PD98050 and H89. In an independent study, adenoviral-overexpression of cyclin D1 in human islets caused a 2.5-fold increase in thymidine incorporation (31). Thus, it will be of interest to determine whether induction of cyclin D1 and proliferation by glucose and the incretin is conveyed by Pax4.

Our data demonstrate that induction of Lpf1 expression was refractory to activin A, betacellulin as well as TGF-β1. To our knowledge, no studies have investigated the impact of these mitogens on the regulation of Lpf1 in mature human islets. However, conditional expression of Smad7 in mouse pancreatic islets which disrupted the TGF-β signaling pathway had no consequence on Pdx1 (mouse homologue of Lpf1) mRNA levels (44) indicating that expression of the transcription factor is not regulated by TGF signaling in either murine or humans. Intriguingly, GLP-1 did not further stimulate Lpf1 expression induced by high glucose concentrations. This is sharp contrast to a single study performed with human foetal pancreas showing that Exendin-4 (a long-acting derivative of GLP-1) up-regulated expression of Lpf1 and accelerated differentiation and maturation of β-cells from precursor cells (45). This apparent discrepancy may be reconciled by the premise that Lpf1 expression during development may be regulated by GLP-1 whereas in mature human islet lpf1 gene transcription is refractory to the incretin. The irrefutable beneficial impact of GLP-1 on β-cell function in human subjects could still involve post-translational regulation of Lpf1. In support of this hypothesis, insulin was recently found to stimulate Lpf1 nuclear translocation in human β-cells correlating with decreased apoptosis (22).

An unexpected finding of the current study was the complete absence of increased human islet proliferation by activin A, betacellulin, glucose or GLP-1. Astonishingly, very few studies have successfully demonstrated growth factor-induced proliferation of adult human β-cells (reviewed in 28) while the impact of GLP-1 on human islet mass expansion remains to be established. A recent study demonstrated that age of donor correlated with decreased proliferative capacity of human β-cells which could account for our inability to stimulate proliferation (46). However, stimulation
of Pax4 expression and the concomitant nuclear translocation of the proliferative marker Id2 by mitogens indicated that growth factor-mediated signalling was functionally adequate to set in motion the replication programme but that downstream activation of target genes was abortive and/or blocked. Overexpression of human Pax4 confirmed this assumption as Id2 expression was not induced while Bcl-xL transcript levels were slightly increased in transduced human islets. The failure of human Pax4 to stimulate downstream target genes did not appear to stem from epigenetic modification, as treatment with 5'-AZA failed to induce expression of either Bcl-xL or Id2 while Pax4 transcription was activated. Interestingly, Pax4 as well as Id2 and Bcl-xL were strongly induced subsequent to 5'-AZA treatment of rat islets suggesting that human Pax4 is less efficient in trans-activating its downstream target genes. This premise was confirmed by EMSA studies and substantiated a previous study showing weak interaction of the human Pax4 protein with its cognate DNA binding sequence when compared with the mouse protein (14). The latter results thus reconcile the observation that overexpression of mouse but not human Pax4 in either human or rat islets was capable of inducing cell replication. The question arises as why rodent Pax4 is a more robust trans-activator when compared with its human counterpart. Alignment of the three proteins revealed an 89% similarity in the DNA binding domains whereas a 50% amino acid divergence was estimated in the carboxy-terminal end (amino acids 230–352) of the rat and mouse sequence to that of the human. This segment of the transcription factor was previously shown to contain a repressor/trans-activator domain (34,47). Interestingly, human insulinomas were shown to contain high levels of a Pax4 variant lacking the carboxy-terminal end of the protein (48). It is therefore tempting to speculate that a nuclear co-factor interacts with the carboxy-terminal end of the human protein regulating DNA binding. This possibility is currently being explored with the use of chimeras containing the amino-terminal end of the human Pax4 linked to the carboxy-terminal end of the mouse protein and the reverse.

Figure 7. Inhibition of DNA methylase induces Pax4 gene expression in human and rat islets. Isolated (A and B) human and (C and D) rat islets were treated with increasing concentrations of the DNA methyltransferase inhibitor, 5'-AzadC (5-AZA) for 72 h. Pax4, Ipfl/Pdx1, Bcl-xL and Id2 transcripts abundance levels were estimated by quantitative RT–PCR. Data are presented as fold change of mRNA levels when compared with control islets normalized to cyclophilin and represent the mean ± SEM of at least three independent experiments performed in duplicates. *P < 0.05; **P < 0.01. (E) EMSA using the radio-labelled G3 element of the glucagon gene promoter and the recombinant proteins mouse and human Pax4-myc. An equal amount of protein was applied in each lane (Fig. 6F). Mouse Pax4 bound strongly to the G3 element whereas the binding of the human Pax4 was less efficient. (F) Western blotting of the recombinant proteins mouse and human Pax4-myc using an anti myc epitope antibody. The same anti-myc serum was used for Western blotting and immunofluorescence.
Alternatively, phosphorylation of serine/threonine residues in this region may also regulate binding activity has previously demonstrated for Pdx1 and NeuroD (49,50).

In summary, this study demonstrates that Pax4 expression is increased in Type 2 diabetic donor islets, an effect which is mediated by high circulating blood glucose and inhibited by increased adiposity. The latter is consistent with the hypothesis that human islet β-cell mass initially expands to compensate for insulin resistance but that there is a long-term failure and development of Type 2 diabetes (51). Consistent with these in vivo findings, we show that Pax4 expression is stimulated in human islets cultured in the presence of mitogens, glucose, insulin and GLP-1. However, due to potential functional divergence in the human and murine Pax4 protein, β-cell replication was not induced under any experimental conditions. The latter highlights the fundamental differences between human and murine/rodent islet physiology and emphasizes the importance of validating results obtained with animal models in human tissues. This dichotomy is further reinforced by recent findings showing that cdk-4 which is essential for murine β-cell replication in totally absent in human islets (52). Thus, elucidating the mechanism by which the activity of the human Pax4 is restrained should facilitate the development of a regenerative therapy for the treatment of diabetes.

**MATERIALS AND METHODS**

**Cell culture**

Pancreatic islets were isolated from 7-week-old male Wistar rats (Elevage Janvier, Le Genest-St-Isle, France) by collagenase digestion (53), handpicked and cultured for 24 h in 11.5 mM glucose/RPMI-1640 supplemented with, 100 Units/ml penicillin, 100 μg/ml streptomycin and 100 μg/ml gentamycin (Sigma-Aldrich, Basel, Switzerland). Freshly isolated human islets were obtained from either the Cell Isolation and Transplantation Laboratory in Geneva or from Ulm University in Ulm and maintained in CMRL-1066 (at 5.6 mM glucose) supplemented with, 100 Units/ml penicillin, 100 μg/ml streptomycin and 100 μg/ml gentamycin for 24 h. Subsequently, human islets were cultured for 24 and 48 h in the presence of increasing concentrations of glucose (5.6, 11, 25 and 33 mM) with or without 10 nM GLP-1 or 250 μM diazoxide. In some instances, 20 μM LY294002 (PI3-kinase inhibitor), 20 μM PD98050 (MAPKK inhibitor) or 10 μM H89 (PKA inhibitor) were individually added to the culture media. Islets were also exposed to 50 nM insulin, 0.5 nM betacellulin (BTC), activin A, TGF-β1 or increasing concentrations of 5′-Aza-2′-deoxycytidine. All chemicals were purchased from Sigma-Aldrich.

Additionally, islets from Type 2 diabetic donors were isolated at the Metabolic Unit at the University of Pisa as previously described (54) and processed for RNA extraction (see below).

**Adenoviral constructions**

The human full length Pax4 cDNA was amplified from human islet-derived RNA and initially cloned into the pcDNA3.1/myc-His expression vector (Invitrogen, Basel, Switzerland). Subsequently, the Pax4-myc DNA fragment was subcloned into the pTRE-Shuttle2 vector (Takara Bio Europe, St-Germain-en-Laye, France). The inducible cassette was then transferred into the Adeno-X viral DNA to generate the recombinant adenovirus Ad-hPax4-myc. The mouse Pax4 cDNA viral construct, Ad-mPax4-myc, was previously described in (5).

**Adenoviral infection of islets**

Human or rat islets were co-infected with either Ad-hPax4-myc or Ad-mPax4-myc along with the adenoviral construct harbouring the tetracycline transcriptional activator (Ad-X Tet-On) at a ratio of 2:1 (3.6 × 10⁷ pfu/ml total viral particles). Islets were rinsed 90 minutes post infection and cultured in fresh media with or without 0.5 μg doxycycline.

**Quantitative real time-PCR (QT-RT-PCR)**

Total RNA from 50 islets was extracted using the Trizol reagent (Invitrogen) and 2 μg was converted into cDNA as previously described (55). Primers for cyclophilin, Id2, Bcl-xL, IL-1β, Fas, FLIP, iNOS and Pax4 were designed using the Primer Express Software (Applera Europe, Rotkreuz, Switzerland) and sequences can be obtained on the Web page of the corresponding author (http://phym.unige.ch/groupes/gauthier/index.php). QT-RT-PCR was performed using an ABI 7000 Sequence Detection System (Applera Europe) and PCR products were quantified using the SYBR Green Core Reagent kit (53). Two distinct amplifications derived from at least 3 independent experiments were performed in duplicate for each transcript and mean values were normalized to the mean value of the reference mRNA cyclophilin. Authenticity of each amplicon was verified by DNA sequencing.

**Immunohistochemistry**

Subsequent to treatment, islet single cell suspensions were obtained using trypsin and concentrated on glass cover slips by cyt centrifugation. Cells were washed with PBS and fixed in 4% paraformaldehyde in PBS for 20 min at room temperature. Mouse and human recombinant Pax4 myc tagged proteins were visualized by immunohistochemistry using an antibody against the myc epitope (dilution 1:200; Invitrogen). Immunochemical detection of Id2 was performed using a rabbit anti-human polyclonal antibody (dilution 1:200, Santa Cruz, USA) while insulin immunostaining was performed as previously described (56). Nuclei were then stained with DAPI (10 μg/ml; Sigma). Cover slips were mounted using DAKO fluorescent mounting medium and visualized using a Zeiss Axioshot I.

**Cell proliferation**

Islets cultured in standard media containing 10% FCS and supplemented with growth factors were labelled with 10 μM BrdU for up to 6 days. Proliferation was estimated using an immuno- histochemical assay kit as described by the manufacturer (BrdU labelling and detection Kit, Roche Diagnostics, Switzerland).
Results are expressed as the percentage of BrdU-positive cells over the total amount of islet cells identified by nuclear DAPI staining and are depicted as a BrdU labelling index.

Recombinant Pax4 preparation and electrophoretic mobility shift assays (EMSSAs)

EMSSAs were performed as previously described (57) using an oligonucleotide corresponding to the rat glucagon gene promoter element G3 (58) along with either human or mouse recombinant Pax4 protein generated from an in vitro transcription and translation system (Promega Inc., Wallisellen, Switzerland).

Western blotting

In vitro produced human and mouse recombinant Pax4 proteins were resolved on a 10% SDS–polyacrylamide gel and transferred to a PVDF membrane. The membrane was blocked in 20 mM Tris–HCl pH 7.5, 150 mM NaCl, 0.1% Tween-20, 5% milk powder and then incubated with a myc-epitope antibody (Invitrogen). Immunoreactive products were revealed by enhanced chemiluminescence (SuperSignal West Pico, Pierce, Rockford, IL, USA) using horseradish peroxidase coupled secondary antibodies.

Statistical analysis

Results are expressed as mean ± SEM. Where indicated, the statistical significance of the differences between groups was estimated by Student’s unpaired t-test. * and ** indicate statistical significance with P < 0.05 and P < 0.01, respectively.

ACKNOWLEDGEMENTS

We are grateful to Dominique Duhamel, Dale Brighouse, Elodie Husi, Danielle Nappey and Deborah Aeberhard for expert technical assistance. We also acknowledge Dr Domenico Bosco of the Cell Isolation and Transplantation Center, University of Geneva. We are indebted to Professor Claes B. Wollheim (C.B.W.) for his guidance and support in this project.

Conflict of Interest statement. None to declare.

FUNDING

This work was funded by the Swiss National Science Foundation (No. 3100A0-107682/1 to B.R.G.), the Juvenile Diabetes Research Foundation (No. 7-2005-1158 to C.B.W.), the European Union (P.M.; Integrated Project EuroDi LSHM-CT-2006-518153 in Framework Programme 6 of the European Community), the European Foundation for the Study of Diabetes (EFSDF)/Pfizer Resource Award (P.M.), the German Research Foundation (DFG, SFB 518, GRK 1041 to B.B.), the Else Kröner-Fresenius Stiftung (B.B.), American Diabetes Association (Junior Faculty Grant 706FJ41 to K.M.) and the Larry L. Hillblom Research Foundation (LLHF grant No. 2005 1C to K.M.). Some human islets were provided through the JDRF award 6-2005-1178 (ECIT: Islet for Research program) while others were obtained from the Islet Cell Resource Consortium, administered by the ABCC and supported by NCRR, NIDDK and JDRF.

REFERENCES


